Recruiting PHASE1 INTERVENTIONAL 4-arm
NCT07465965
A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults
A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic (PK) of Single-dose Administration of Semaglutide Nasal Spray (WL1006) in Adult Overweight or Obese Participants
Sponsor: Shanghai World Leader Pharmaceutical Co., Ltd.
Conditions
Obesity Overweight
Interventions
Placebo Semaglutide Injection Semaglutide Nasal Spray
Updated 1 time since 2026 Last updated: Mar 6, 2026 Started: Mar 2, 2026 Primary completion: Aug 21, 2026 Completion: Aug 30, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE1 trial investigates Obesity and Overweight and is currently actively recruiting participants. Shanghai World Leader Pharmaceutical Co., Ltd. leads this study, which shows 1 recorded version since 2026 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
1 version recorded Recruiting — PHASE1
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Shanghai World Leader Pharmaceutical Co., Ltd.
Data source: Shanghai World Leader Pharmaceutical Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .